deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02547922

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis (TULIP-LN1)

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis

Sponsor: AstraZeneca

Conditions Lupus Nephritis
Interventions Anifrolumab Placebo
Updated 24 times since 2017 Last updated: Oct 28, 2021 Started: Nov 4, 2015 Primary completion: Nov 26, 2019 Completion: Jan 18, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lupus Nephritis, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 24 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Aug 2019 · 9 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 19 earlier versions

  1. Feb 2021 — Dec 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  5. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Aug 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Nov 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  10. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  11. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  12. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  13. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  15. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  16. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  17. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  18. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Parexel
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Arequipa, Peru , Aurora, United States , Barcelona, Spain , Belgrade, Serbia , Berlin, Germany , Bordeaux, France , Boston, United States , Brussels, Belgium , Budapest, Hungary and 55 more locations